by Cheryl Scott- Bioprocess international
Consultants from ProPharma express optimism about the trajectory of cell and gene therapy despite technical and logistical difficulties remaining in the field. A combination of automation, advanced modeling, decentralized manufacturing, and increasingly supportive regulatory frameworks is creating new possibilities for bringing potentially transformative therapies to patients around the world.
The cell/gene therapy (CGT) industry stands at a crossroads where groundbreaking science meets the practicalities of manufacturing, regulation, and commercialization. This past spring, I spoke with ProPharma consultants Robert Beall (vice president of the quality and compliance group) and Simona Guidi (head of the CGT group), who shared insights into the unique obstacles and opportunities shaping this transformative field.
